Acta Scientific Gastrointestinal Disorders (ASGIS)(ISSN: 2582-1091)

Research Article Volume 5 Issue 10

Are Sufficient Induction Dose of Anti-TNF Drug for Avoid Failure Pharmacokinetic in Patients with Inflammatory Bowel Disease? A Study in a Real World Setting

Carles Iniesta Navalón1*, Lidia Díaz Serrano2, Lorena Rentero Redondo1, María Ángeles Nieto Vitoria2, Consolación Pastor Mondéjar1, Rosa Gómez Espín2 and Isabel Nicolás De Prado2

1PhD, Department of Hospital Pharmacy, Reina Sofia Hospital of Murcia, Spain
2MD, Department of Gastroenterology, Reina Sofia Hospital of Murcia, Spain

*Corresponding Author: Carles Iniesta Navalón, PhD, Department of Hospital Pharmacy, Reina Sofia Hospital of Murcia, Spain.

Received: September 14, 2022; Published: September 28, 2022

Abstract

Objectives: Pharmacokinetic processes associated increased drug clearance could play a key role in primary no-responders to anti-TNF drug in inflammatory bowel disease patients. To our knowledge, little is known about whether drug exposures after induction doses are sufficient to avoid pharmacokinetic failure in real life. The main objective of this study was to determine the proportion of patient adalimumab and infliximab-treated, with pharmacokinetic failure at induction period, and to investigate the factors associated with increase clearance.

Methods: We conducted a retrospective observational study. Patients starting treatment with adalimumab or infliximab during May 2017 to June 2021 were potentially eligible for the study. The primary outcome was to determine the proportion of patients with drug concentration at induction period, and to investigate baseline patient-related characteristics affecting to drug elimination. Individual pharmacokinetic parameters were estimate by Bayesian method for each patient.

Results: A total of 101 patients were included in the study. The proportion of patients with serum concentrations in the therapeutic range was higher in patients treated with adalimumab than infliximab (74.5% vs. 40.0%, respectively; p < 0.001). After multivariate analysis, the factors associated with a short half-life (<163 hours) for infliximab were: diagnosis UC (OR: 5.62 [CI95% 1.01 -32.5]), serum albumin (OR: 0.26 [CI 95%: 0.03 - 0.90]), and anti-TNF-ɑ previous treatment (OR: 8.86 [CI 95%: 1.10-71.48]).No association were found for ADA.

Conclusion: The findings of this study justify the early measurement of drug levels to be able to optimize therapy appropriately and avoid lack of response, especially in patients at risk.

Keywords: Infliximab; Adalimumab; Therapeutic Drug Monitoring; Induction; Inflammatory Bowel Disease; Pharmacokinetic

References

  1. Hanauer SB., et al. “Human Anti-Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial”. Gastroenterology 130 (2006): 323-333.
  2. Rutgeerts P., et al. “Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis”. The New England Journal of Medicine 353 (2005): 2467-2476.
  3. Colombel JF., et al. “Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial”. Gastroenterology 132 (2007): 52-65.
  4. Papamichael K., et al. “Therapeutic Drug Monitoring during Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window”. Inflammatory Bowel Disease 23 (2017): 1510-1515.
  5. Sparrow MP., et al. “Therapeutic Drug Monitoring of Biologics during Induction to Prevent Primary Non-Response”. Journal of Crohn's and Colitis 14 (2020): 543-556.
  6. Frymoyer A., et al. “Infliximab dosing strategies and predicted trough exposure in children with Crohn disease”. Journal of Pediatric Gastroenterology and Nutrition 62 (2016): 723-727.
  7. Papamichael K., et al. “Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases”. Clinical Gastroenterology and Hepatology 17 (2019): 1655-1668.
  8. Casteele N Vande., et al. “Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease”. Gastroenterology 148 (2015): 1320-1329.
  9. Candel MG., et al. “Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease ORIGINAL PAPERS”. Revista Española de Enfermedades Digestivas 112 (2020): 360-366.
  10. Papamichael K., et al. “Post-induction adalimumab concentration is associated with short-term mucosal healing in patients with ulcerative colitis”. Journal of Crohn's and Colitis 11 (2017): 53-59.
  11. Zittan E., et al. “Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn’s Disease”. Clinical and Translational Gastroenterology 12 (2021): e00401.
  12. Liefferinckx C., et al. “Infliximab Trough Levels at Induction to Predict Treatment Failure during Maintenance”. Inflammatory Bowel Disease 23 (2017): 1371-1381.
  13. Verstockt B., et al. “Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn’s disease patients: the usefulness of rapid testing”. Alimentary Pharmacology and Therapeutics 48 (2018): 731-739.
  14. Toyonaga T., et al. “Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome”. PLoS One 12 (2017).
  15. Kennedy NA., et al. “Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study”. Lancet Gastroenterology and Hepatology 4 (2019): 341-353.
  16. Naviglio S., et al. “How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease”. Expert Review of Gastroenterology and Hepatology 12 (2018): 797-810.
  17. Satsangi J., et al. “The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications”. Gut 55 (2006): 749-753.
  18. Ternant D., et al. “Pharmacokinetics of adalimumab in Crohn’s disease”. European Journal of Clinical Pharmacology 71 (2015): 1155-1157.
  19. Adedokun OJ., et al. “Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn’s Disease”. Gastroenterology 154 (2018): 1660-1671.
  20. Cheifetz AS., et al. “A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease”. American Journal of Gastroenterology 116 (2021): 2014-2025.
  21. Papamichael K., et al. “Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: Evolution in the definition and management of primary nonresponse”. Inflammatory Bowel Disease 21 (2015): 182-197.
  22. Brandse JF., et al. “Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis”. Gastroenterology 149 (2015): 350-355.
  23. Bertani L., et al. “Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study”. Clinical and Translational Gastroenterology 11 (2020):
  24. Dotan I., et al. “Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: A population pharmacokinetic study”. Inflammatory Bowel Disease 20 (2014): 2247-2259.
  25. Papamichael K., et al. “Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis”. Clinical Gastroenterology and Hepatology 14 (2016): 543-549.
  26. Davidov Y., et al. “Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn’s Disease”. Journal of Crohns Colitis 11 (2017): 549-555.
  27. Gil Candel M., et al. “Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients”. Revista Espanola de enfermedades 112 (2020): 590-597.
  28. Strik AS., et al. “Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial”. Scandinavian Journal of Gastroenterology 56 (2021): 145-154.
  29. Frymoyer A., et al. “Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease”. Journal of Pediatric Gastroenterology and Nutrition 65 (2017): 639-645.
  30. Dubinsky MC., et al. “Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity”. Inflammatory Bowel Disease (2022).

Citation

Citation: Carles Iniesta Navalón., et al. “Are Sufficient Induction Dose of Anti-TNF Drug for Avoid Failure Pharmacokinetic in Patients with Inflammatory Bowel Disease? A Study in a Real World Setting". Acta Scientific Gastrointestinal Disorders 5.10 (2022): 37-44.

Copyright

Copyright: © 2022 Carles Iniesta Navalón., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 15, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US